Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
BioMarin Pharmaceutical (BMRN) has just given investors a packed update, including second quarter 2026 results, fresh earnings guidance for the rest of the year, and a new shelf registration filing.
See our latest analysis for BioMarin Pharmaceutical.
At a share price of US$67.36, BioMarin Pharmaceutical has seen a 90-day share price return of 35.62% and a 1-year total shareholder return of 17.07%, although the 3-year total shareholder return is down 24.36%. This points to improving short term momentum against a weaker longer term record.
If you are weighing rare disease exposure against other opportunities in healthcare, this can be a good moment to broaden your search and check out 42 healthcare AI stocks
Bulls point to BioMarin Pharmaceutical's rare disease portfolio and upgraded 2026 revenue outlook. Bears focus on thinner margins, higher leverage and the new shelf registration. Which side does the current valuation really support next?
Compared with BioMarin Pharmaceutical's last close at $67.36, the most widely followed narrative points to a higher fair value of $87.85 based on discounted future cash flows, using a 7.32% discount rate and detailed long term earnings assumptions.
Analysts expect earnings to reach $1.3 billion (and earnings per share of $6.72) by about June 2029, up from $268.7 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $2.1 billion in earnings, and the most bearish expecting $759.4 million.
Want to see what earnings, margins and growth mix would need to line up for that valuation to hold? The full narrative spells out the cash flow path, the profitability step up and the multiple the stock would need to carry by 2029.
Result: Fair Value of $87.85 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, BioMarin Pharmaceutical still faces pressure if competition in rare disease treatments intensifies or if higher R&D and SG&A spending weighs on future profitability.
Find out about the key risks to this BioMarin Pharmaceutical narrative.
With BioMarin Pharmaceutical pulling strong opinions on both risks and rewards, it makes sense to pressure test the story for yourself. To see the key issues investors are focused on from both sides, start with the 3 key rewards and 3 important warning signs
Do not stop with BioMarin Pharmaceutical. Use the Simply Wall Street Screener to spot other stocks that could fit your portfolio and keep your ideas fresh.
Target steady compounding potential by reviewing companies with strong cash flows and quality fundamentals through the 52 high quality undervalued stocks
Strengthen your capital base by focusing on companies with robust finances and dependable balance sheets using the solid balance sheet and fundamentals stocks screener (51 results)
Get ahead of the crowd by checking a screener containing 20 high quality undiscovered gems before attention and capital rush in.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BMRN.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]